The French start-up REGEnLIFE, which Opinion Internationale has been following since 2022, co-founded by Guillaume Blivet [right] and whose prestigious Scientific Advisory Board is chaired by Prof. Jacques Touchon [left], has just been named a finalist in the ‘Best Start-up’ category of the 2025 Galien USA Prize (The Galien Foundation), considered the “Nobel Prize” of medical research.
The awards ceremony will take place on 30 October 2025 at the American Museum of Natural History in New York, attended by the world’s leading figures in healthcare innovation. Each year, this international award recognises the most promising innovations in human health, selected on the basis of purely scientific criteria and their impact on public health.
A breakthrough innovation targeting the brain… and the gut
REGEnLIFE is developing a non-invasive photomedical technology that acts simultaneously on the brain and the gut. This dual-targeting approach, inspired by recent advances in the brain-gut-microbiota axis, aims to reduce neuroinflammation, promote cellular repair and improve cognition. The aim is to provide an innovative therapeutic solution for neurodegenerative diseases, such as Alzheimer’s disease, by targeting several key biological pathways, without the use of pharmaceutical compounds, surgery or ionising radiation.
The patented, ergonomic, modular and software-controlled medical device is designed to meet clinical and regulatory requirements whilst anticipating wider-scale use within healthcare systems.
A strategic asset for technological sovereignty
With a robust clinical pipeline and an international portfolio of patents, REGEnLIFE – founded in Occitanie and part of the MedVallée ecosystem in Montpellier – is at the forefront of the global race for medical innovation, in a rapidly growing market driven by an ageing population.
His appointment reflects the vitality of France’s deeptech and neurotech ecosystem and its potential for international expansion, within a sector that is strategic for health and technological sovereignty. It also sends a positive signal regarding the ability of French healthtech start-ups to compete with international leaders.
This recognition could accelerate the formation of new R&D partnerships and support the next round of fundraising, scheduled for before the end of 2026, to propel the company to market.
« This appointment recognises our ambitious research and development work, driven by a clear vision: to provide patients with safe, effective and scientifically sound solutions. It is also a significant recognition of the efforts of our entire team and our partners », said Guillaume Blivet, co-founder and Head of Innovation.
“The photobiomodulation technique developed by REGEnLIFE could be one of the key elements of a future therapeutic strategy aimed at combating this terrible disease,” emphasises Professor Jacques Touchon, Chair of REGEnLIFE’s Scientific Advisory Board and a recognised specialist in Alzheimer’s disease.
With this nomination for the Prix Galien USA, REGEnLIFE has cemented its position among the emerging global players capable of transforming the management of neurodegenerative diseases, combining scientific excellence, human impact and economic potential.
